OmniAb Inc（OABI）财务数据OABIOmniAb Inc

OmniAb Inc (OABI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is License and milestone revenue, accounting for 70.9% of total sales, equivalent to $9.52M. Other significant revenue streams include Service revenue and xPloration revenue. Understanding this composition is critical for investors evaluating how OABI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, OmniAb Inc maintains a gross margin of 72.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -49.47%, while the net margin is -43.67%. These profitability ratios, combined with a Return on Equity (ROE) of -16.95%, provide a clear picture of how effectively OABI converts its operational activities into shareholder value.

In the context of the broader market, OABI competes directly with industry leaders such as CASS and LINC. With a market capitalization of $721.14M, it holds a leading position in the sector. When comparing efficiency, OABI's gross margin of 72.69% stands against CASS's 92.56% and LINC's 58.17%. Such benchmarking helps identify whether OmniAb Inc is trading at a premium or discount relative to its financial performance.

OmniAb has demonstrated significant revenue growth, with Q2 2026 revenue reaching $13.4 million, a 244% increase year-over-year. Despite this, the company has been reporting net losses, with a net income of -5.9 million in Q2 2026 and a gross margin of 72.69%.